UK Court Invalidates AstraZeneca's Seroquel XR Patent

Law360, New York (March 22, 2012, 6:27 PM EDT) -- The U.K.'s High Court of Justice has invalidated an AstraZeneca AB patent for the extended release version of the company's anti-psychotic drug Seroquel XR, the drugmaker said Thursday.

The patent for the drug's formulation was challenged in British court by a host of generic-drug makers, including units of Teva Pharmaceutical Industries Ltd. and Sandoz Inc. as well as Accord Healthcare Ltd. and its parent Intas Pharmaceuticals Ltd.

The High Court of Justice's decision, which is the first such ruling finding the patent invalid in any court...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.